KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer (mG/GEJC): A double-blind, randomized, placebo-controlled phase 3 study Meeting Abstract
| Authors: | Janjigian, Y. Y.; Bang, Y. J.; Fuchs, C. S.; Qin, S.; Satoh, T.; Shitara, K.; Tabernero, J.; Van Cutsem, E.; Cao, Z. A.; Chen, X.; Kang, S. P.; Shih, C. S.; Chung, H. C. |
| Abstract Title: | KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer (mG/GEJC): A double-blind, randomized, placebo-controlled phase 3 study |
| Meeting Title: | 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 37 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2019 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2019-05-20 |
| Start Page: | 257s |
| Language: | English |
| ACCESSION: | WOS:000487345803330 |
| DOI: | 10.1200/JCO.2019.37.15_suppl.TPS4146 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: TPS4146 -- Source: Wos |
